A natural plant compound called dehydrocostus lactone significantly reduced fat buildup in liver cells and improved liver health markers in mice with fatty liver disease, according to Gram Research analysis of a 2026 study. The compound works by activating proteins that help cells burn fat more efficiently and prevent fat accumulation, while also restoring healthy levels of important metabolic molecules. However, this is early-stage research in animals, and human studies are needed before this could become a medical treatment.
Researchers discovered that a natural compound called dehydrocostus lactone (DHL) may help treat fatty liver disease by improving how the body burns fat. In a study using mice with both fatty liver disease and heart disease risk factors, DHL reduced fat buildup in the liver, lowered cholesterol and triglyceride levels, and improved liver health markers. The compound works by activating special proteins that help cells burn fat more efficiently and prevent fat from accumulating inside liver cells. These findings suggest DHL could become a new treatment option for people with metabolic dysfunction-associated fatty liver disease.
Key Statistics
A 2026 research study found that dehydrocostus lactone markedly reduced hepatic lipid accumulation and collagen deposition in mice with fatty liver disease, as evidenced by decreased Oil Red O-positive areas and reduced total cholesterol and triglyceride levels compared with high-fat diet controls.
According to research reviewed by Gram, the compound improved liver fibrosis and normalized serum transaminase levels (liver damage markers) in mice without significantly affecting body weight, suggesting targeted effects on liver metabolism.
The 2026 study demonstrated that dehydrocostus lactone upregulated PPAR-alpha and its downstream target CPT1-beta to enhance fatty acid oxidation while suppressing FABP5 to reduce intracellular lipid retention in liver tissue.
Metabolomic profiling in the research revealed that dehydrocostus lactone treatment restored carnitine pools and vitamin A levels in liver tissue, indicating improved mitochondrial fatty acid transport and hepatic function.
The Quick Take
- What they studied: Whether a natural plant compound called dehydrocostus lactone could reduce fat buildup in the liver and improve liver health in animals with fatty liver disease and heart disease risk.
- Who participated: Laboratory mice that were genetically modified to develop fatty liver disease and heart disease, fed a high-fat diet for 10 weeks, then treated with different doses of the compound or a standard liver medication.
- Key finding: The compound significantly reduced fat accumulation in liver cells, lowered cholesterol and triglyceride levels, and improved liver damage markers compared to untreated mice with the disease.
- What it means for you: This research suggests a potential new natural treatment for fatty liver disease, though human studies are needed before it could be used as medicine. People with fatty liver disease should continue following their doctor’s current treatment recommendations.
The Research Details
Scientists used specially bred laboratory mice that naturally develop fatty liver disease and heart disease when eating a high-fat diet. They fed these mice unhealthy food for 10 weeks to create the disease, then gave some mice different amounts of dehydrocostus lactone (a compound extracted from plants) while others received a standard liver medication or no treatment.
The researchers examined the mice’s livers using multiple methods: they looked at liver tissue under a microscope to see fat and scar buildup, measured cholesterol and triglyceride levels in the blood, and checked liver enzyme levels that indicate damage. They also performed advanced genetic and chemical analysis of liver tissue to understand exactly how the compound worked at the molecular level.
This type of study is important because it allows researchers to test new treatments in a controlled environment before considering human trials, and to understand the detailed biological mechanisms of how a treatment works.
Using both microscopic examination and advanced molecular analysis together provides strong evidence about how the treatment works. This combination approach helps researchers understand not just that something works, but exactly why it works, which is crucial for developing safe and effective medicines.
This is a preclinical laboratory study using animal models, which means results cannot be directly applied to humans yet. The study used established research methods and multiple ways to measure outcomes, which strengthens confidence in the findings. However, animal studies don’t always produce the same results in humans, so human clinical trials would be necessary before this could become a medical treatment.
What the Results Show
The compound dehydrocostus lactone significantly reduced fat accumulation in liver cells compared to untreated mice with fatty liver disease. Mice treated with the compound showed lower cholesterol and triglyceride levels in their blood, indicating improved lipid metabolism. The compound also reduced liver scarring (fibrosis) and normalized liver enzyme levels that indicate cellular damage, suggesting improved overall liver health.
Importantly, these improvements occurred without causing weight loss or other obvious side effects in the treated mice. The compound worked similarly to simvastatin, a standard medication used to treat liver disease, but through different biological mechanisms.
The molecular analysis revealed that the compound works by activating a protein called PPAR-alpha, which acts like a master switch for fat-burning in liver cells. This activation increases production of another protein (CPT1-beta) that helps transport fatty acids into mitochondria where they can be burned for energy. The compound also reduced levels of a protein (FABP5) that normally causes fat to accumulate inside cells. Additionally, the treatment restored healthy levels of carnitine and vitamin A in liver tissue, both important for proper liver function and energy metabolism.
This research builds on previous studies showing that PPAR-alpha activation can improve fatty liver disease. The novel contribution here is demonstrating that dehydrocostus lactone activates this pathway while also working through multiple other mechanisms simultaneously. This multi-targeted approach may explain why the compound was effective in mice with both fatty liver disease and atherosclerosis risk, whereas many previous treatments focused on only one aspect of the disease.
This study was conducted only in laboratory mice with genetically engineered disease, not in humans with naturally occurring fatty liver disease. The sample size of mice is not specified in the available information. Results from animal studies often don’t translate directly to humans due to differences in metabolism and physiology. The study doesn’t provide information about potential side effects in humans or optimal dosing for human use. Long-term effects and safety in humans remain unknown.
The Bottom Line
Based on this preclinical research, dehydrocostus lactone shows promise as a potential future treatment for fatty liver disease, but it is not yet ready for human use. Current evidence-based recommendations for fatty liver disease remain: maintain a healthy weight, eat a balanced diet low in processed foods and added sugars, exercise regularly, and work with your doctor on any medical treatments. People with fatty liver disease should not attempt to use this compound without medical supervision, as human safety and efficacy data do not yet exist.
This research is most relevant to people with metabolic dysfunction-associated fatty liver disease (MAFLD), particularly those who also have heart disease risk factors. Researchers and pharmaceutical companies developing new liver disease treatments should pay attention to these findings. People with fatty liver disease should be aware of this emerging research but should continue following their doctor’s current treatment recommendations. This research is not yet applicable to general health decisions.
This is early-stage research. If the compound moves forward to human clinical trials, it would typically take 5-10 years of testing before it could potentially become available as a medication. Realistic expectations are that this compound would need to progress through multiple phases of human testing to establish safety and effectiveness before any medical use.
Frequently Asked Questions
What is dehydrocostus lactone and where does it come from?
Dehydrocostus lactone (DHL) is a natural compound extracted from plants, specifically from species in the Asteraceae family. In this 2026 study, researchers tested whether this plant-derived compound could treat fatty liver disease by improving how liver cells burn fat.
Can I use dehydrocostus lactone to treat my fatty liver disease right now?
No, this compound is not yet available as a medical treatment for humans. This was early-stage laboratory research in mice. Human clinical trials would be necessary to establish safety and effectiveness before it could be prescribed as medicine.
How does dehydrocostus lactone help reduce liver fat?
The compound activates a protein called PPAR-alpha that acts like a master switch for fat-burning in liver cells. This increases production of proteins that transport fatty acids into mitochondria where they’re burned for energy, while also reducing fat accumulation inside cells.
Is this treatment better than current fatty liver disease medications?
In mice, dehydrocostus lactone worked similarly to simvastatin (a standard liver medication) but through different biological pathways. Whether it would be better in humans is unknown and would require clinical trials to determine.
When might dehydrocostus lactone become available as a treatment?
If this compound advances to human clinical trials, it would typically take 5-10 years of testing before it could potentially become available as a medication. Currently, it remains in early research stages and is not approved for human use.
Want to Apply This Research?
- Users with fatty liver disease could track liver health markers through their healthcare provider: measure liver enzyme levels (ALT and AST) every 3 months and triglyceride/cholesterol levels every 6 months to monitor disease progression or improvement.
- While waiting for potential future treatments, users can implement proven lifestyle changes: log daily diet to reduce processed foods and added sugars, track weekly exercise minutes (aiming for 150 minutes moderate activity), and monitor weight trends to support liver health.
- Create a quarterly health review reminder to check lab results with your doctor, track dietary improvements month-to-month, and monitor energy levels and abdominal symptoms as indirect indicators of liver health improvement.
This article discusses early-stage laboratory research in animals and does not represent approved medical treatment for humans. Dehydrocostus lactone is not currently available as a medical treatment and has not been tested for safety or effectiveness in humans. People with fatty liver disease should continue following their doctor’s current treatment recommendations and should not attempt to use this compound without medical supervision. This research is informational only and should not be used to make medical decisions. Always consult with a qualified healthcare provider before starting any new treatment or supplement.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.